nodes	percent_of_prediction	percent_of_DWPC	metapath
Lubiprostone—CLCN2—artery—systemic scleroderma	0.101	0.271	CbGeAlD
Lubiprostone—CLCN2—endothelium—systemic scleroderma	0.0853	0.228	CbGeAlD
Lubiprostone—CLCN2—blood vessel—systemic scleroderma	0.0787	0.211	CbGeAlD
Lubiprostone—CLCN2—smooth muscle tissue—systemic scleroderma	0.0369	0.0988	CbGeAlD
Lubiprostone—CLCN2—lung—systemic scleroderma	0.0243	0.0652	CbGeAlD
Lubiprostone—CBR1—skin of body—systemic scleroderma	0.0146	0.0391	CbGeAlD
Lubiprostone—CBR1—digestive system—systemic scleroderma	0.0117	0.0313	CbGeAlD
Lubiprostone—CBR1—tendon—systemic scleroderma	0.0111	0.0298	CbGeAlD
Lubiprostone—CBR1—lung—systemic scleroderma	0.00975	0.0261	CbGeAlD
Lubiprostone—Headache—Pentoxifylline—systemic scleroderma	0.00141	0.00225	CcSEcCtD
Lubiprostone—Feeling abnormal—Captopril—systemic scleroderma	0.00141	0.00225	CcSEcCtD
Lubiprostone—Chest pain—Mycophenolic acid—systemic scleroderma	0.0014	0.00224	CcSEcCtD
Lubiprostone—Myalgia—Mycophenolic acid—systemic scleroderma	0.0014	0.00224	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Captopril—systemic scleroderma	0.0014	0.00223	CcSEcCtD
Lubiprostone—Anxiety—Mycophenolic acid—systemic scleroderma	0.0014	0.00223	CcSEcCtD
Lubiprostone—Asthenia—Mometasone—systemic scleroderma	0.0014	0.00223	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00139	0.00222	CcSEcCtD
Lubiprostone—Tremor—Lisinopril—systemic scleroderma	0.00139	0.00222	CcSEcCtD
Lubiprostone—Discomfort—Mycophenolic acid—systemic scleroderma	0.00139	0.00221	CcSEcCtD
Lubiprostone—Nervous system disorder—Leflunomide—systemic scleroderma	0.00138	0.0022	CcSEcCtD
Lubiprostone—Ill-defined disorder—Lisinopril—systemic scleroderma	0.00138	0.0022	CcSEcCtD
Lubiprostone—Tachycardia—Leflunomide—systemic scleroderma	0.00138	0.00219	CcSEcCtD
Lubiprostone—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00137	0.00219	CcSEcCtD
Lubiprostone—Skin disorder—Leflunomide—systemic scleroderma	0.00137	0.00218	CcSEcCtD
Lubiprostone—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00136	0.00217	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00136	0.00217	CcSEcCtD
Lubiprostone—Abdominal pain—Captopril—systemic scleroderma	0.00135	0.00216	CcSEcCtD
Lubiprostone—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00215	CcSEcCtD
Lubiprostone—Oedema—Mycophenolic acid—systemic scleroderma	0.00134	0.00214	CcSEcCtD
Lubiprostone—Anorexia—Leflunomide—systemic scleroderma	0.00134	0.00214	CcSEcCtD
Lubiprostone—Nausea—Pentoxifylline—systemic scleroderma	0.00134	0.00214	CcSEcCtD
Lubiprostone—Malaise—Lisinopril—systemic scleroderma	0.00134	0.00213	CcSEcCtD
Lubiprostone—Diarrhoea—Mometasone—systemic scleroderma	0.00133	0.00212	CcSEcCtD
Lubiprostone—Syncope—Lisinopril—systemic scleroderma	0.00133	0.00212	CcSEcCtD
Lubiprostone—Shock—Mycophenolic acid—systemic scleroderma	0.00132	0.00211	CcSEcCtD
Lubiprostone—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00132	0.0021	CcSEcCtD
Lubiprostone—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00131	0.00209	CcSEcCtD
Lubiprostone—Palpitations—Lisinopril—systemic scleroderma	0.00131	0.00209	CcSEcCtD
Lubiprostone—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00131	0.00209	CcSEcCtD
Lubiprostone—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00131	0.00208	CcSEcCtD
Lubiprostone—Loss of consciousness—Lisinopril—systemic scleroderma	0.0013	0.00208	CcSEcCtD
Lubiprostone—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.0013	0.00207	CcSEcCtD
Lubiprostone—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.0013	0.00207	CcSEcCtD
Lubiprostone—Cough—Lisinopril—systemic scleroderma	0.00129	0.00207	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.00129	0.00206	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00129	0.00206	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00128	0.00205	CcSEcCtD
Lubiprostone—Anorexia—Mycophenolic acid—systemic scleroderma	0.00128	0.00204	CcSEcCtD
Lubiprostone—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.00128	0.00204	CcSEcCtD
Lubiprostone—Abdominal distension—Prednisone—systemic scleroderma	0.00127	0.00203	CcSEcCtD
Lubiprostone—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00127	0.00203	CcSEcCtD
Lubiprostone—Chest pain—Lisinopril—systemic scleroderma	0.00126	0.00202	CcSEcCtD
Lubiprostone—Myalgia—Lisinopril—systemic scleroderma	0.00126	0.00202	CcSEcCtD
Lubiprostone—Anxiety—Lisinopril—systemic scleroderma	0.00126	0.00201	CcSEcCtD
Lubiprostone—Dyspnoea—Leflunomide—systemic scleroderma	0.00126	0.002	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00125	0.002	CcSEcCtD
Lubiprostone—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00199	CcSEcCtD
Lubiprostone—Discomfort—Lisinopril—systemic scleroderma	0.00125	0.00199	CcSEcCtD
Lubiprostone—Lethargy—Methotrexate—systemic scleroderma	0.00125	0.00199	CcSEcCtD
Lubiprostone—Dyspepsia—Leflunomide—systemic scleroderma	0.00124	0.00198	CcSEcCtD
Lubiprostone—Vomiting—Mometasone—systemic scleroderma	0.00124	0.00197	CcSEcCtD
Lubiprostone—Dry mouth—Lisinopril—systemic scleroderma	0.00124	0.00197	CcSEcCtD
Lubiprostone—Feeling abnormal—Azathioprine—systemic scleroderma	0.00123	0.00196	CcSEcCtD
Lubiprostone—Rash—Mometasone—systemic scleroderma	0.00123	0.00196	CcSEcCtD
Lubiprostone—Asthenia—Captopril—systemic scleroderma	0.00123	0.00196	CcSEcCtD
Lubiprostone—Dermatitis—Mometasone—systemic scleroderma	0.00123	0.00196	CcSEcCtD
Lubiprostone—Decreased appetite—Leflunomide—systemic scleroderma	0.00122	0.00195	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00122	0.00195	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00122	0.00195	CcSEcCtD
Lubiprostone—Headache—Mometasone—systemic scleroderma	0.00122	0.00195	CcSEcCtD
Lubiprostone—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00122	0.00194	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00122	0.00194	CcSEcCtD
Lubiprostone—Fatigue—Leflunomide—systemic scleroderma	0.00121	0.00194	CcSEcCtD
Lubiprostone—Oedema—Lisinopril—systemic scleroderma	0.00121	0.00193	CcSEcCtD
Lubiprostone—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.00121	0.00192	CcSEcCtD
Lubiprostone—Pain—Leflunomide—systemic scleroderma	0.0012	0.00192	CcSEcCtD
Lubiprostone—Constipation—Leflunomide—systemic scleroderma	0.0012	0.00192	CcSEcCtD
Lubiprostone—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.0012	0.00191	CcSEcCtD
Lubiprostone—Shock—Lisinopril—systemic scleroderma	0.00119	0.0019	CcSEcCtD
Lubiprostone—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00118	0.00189	CcSEcCtD
Lubiprostone—Tachycardia—Lisinopril—systemic scleroderma	0.00118	0.00189	CcSEcCtD
Lubiprostone—Abdominal pain—Azathioprine—systemic scleroderma	0.00118	0.00188	CcSEcCtD
Lubiprostone—Skin disorder—Lisinopril—systemic scleroderma	0.00118	0.00188	CcSEcCtD
Lubiprostone—Malaise—Mycophenolate mofetil—systemic scleroderma	0.00117	0.00187	CcSEcCtD
Lubiprostone—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00117	0.00187	CcSEcCtD
Lubiprostone—Diarrhoea—Captopril—systemic scleroderma	0.00117	0.00187	CcSEcCtD
Lubiprostone—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00117	0.00186	CcSEcCtD
Lubiprostone—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00117	0.00186	CcSEcCtD
Lubiprostone—Feeling abnormal—Leflunomide—systemic scleroderma	0.00116	0.00185	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00116	0.00185	CcSEcCtD
Lubiprostone—Fatigue—Mycophenolic acid—systemic scleroderma	0.00116	0.00185	CcSEcCtD
Lubiprostone—Nausea—Mometasone—systemic scleroderma	0.00116	0.00184	CcSEcCtD
Lubiprostone—Anorexia—Lisinopril—systemic scleroderma	0.00115	0.00184	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00115	0.00184	CcSEcCtD
Lubiprostone—Weight increased—Prednisone—systemic scleroderma	0.00115	0.00184	CcSEcCtD
Lubiprostone—Pain—Mycophenolic acid—systemic scleroderma	0.00115	0.00183	CcSEcCtD
Lubiprostone—Constipation—Mycophenolic acid—systemic scleroderma	0.00115	0.00183	CcSEcCtD
Lubiprostone—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00183	CcSEcCtD
Lubiprostone—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00182	CcSEcCtD
Lubiprostone—Cough—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00181	CcSEcCtD
Lubiprostone—Dizziness—Captopril—systemic scleroderma	0.00113	0.0018	CcSEcCtD
Lubiprostone—Abdominal pain—Leflunomide—systemic scleroderma	0.00111	0.00178	CcSEcCtD
Lubiprostone—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00111	0.00177	CcSEcCtD
Lubiprostone—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00177	CcSEcCtD
Lubiprostone—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00177	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.0011	0.00176	CcSEcCtD
Lubiprostone—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.0011	0.00176	CcSEcCtD
Lubiprostone—Hypersensitivity—Azathioprine—systemic scleroderma	0.0011	0.00175	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.0011	0.00175	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.0011	0.00175	CcSEcCtD
Lubiprostone—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00109	0.00174	CcSEcCtD
Lubiprostone—Vomiting—Captopril—systemic scleroderma	0.00109	0.00173	CcSEcCtD
Lubiprostone—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00108	0.00173	CcSEcCtD
Lubiprostone—Dyspnoea—Lisinopril—systemic scleroderma	0.00108	0.00172	CcSEcCtD
Lubiprostone—Rash—Captopril—systemic scleroderma	0.00108	0.00172	CcSEcCtD
Lubiprostone—Dermatitis—Captopril—systemic scleroderma	0.00108	0.00172	CcSEcCtD
Lubiprostone—Headache—Captopril—systemic scleroderma	0.00107	0.00171	CcSEcCtD
Lubiprostone—Dyspepsia—Lisinopril—systemic scleroderma	0.00107	0.0017	CcSEcCtD
Lubiprostone—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00106	0.0017	CcSEcCtD
Lubiprostone—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00169	CcSEcCtD
Lubiprostone—Decreased appetite—Lisinopril—systemic scleroderma	0.00105	0.00168	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00105	0.00167	CcSEcCtD
Lubiprostone—Fatigue—Lisinopril—systemic scleroderma	0.00104	0.00167	CcSEcCtD
Lubiprostone—Shock—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00167	CcSEcCtD
Lubiprostone—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00166	CcSEcCtD
Lubiprostone—Hypersensitivity—Leflunomide—systemic scleroderma	0.00104	0.00166	CcSEcCtD
Lubiprostone—Pain—Lisinopril—systemic scleroderma	0.00104	0.00165	CcSEcCtD
Lubiprostone—Constipation—Lisinopril—systemic scleroderma	0.00104	0.00165	CcSEcCtD
Lubiprostone—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00165	CcSEcCtD
Lubiprostone—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00164	CcSEcCtD
Lubiprostone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00164	CcSEcCtD
Lubiprostone—Diarrhoea—Azathioprine—systemic scleroderma	0.00102	0.00163	CcSEcCtD
Lubiprostone—Nausea—Captopril—systemic scleroderma	0.00102	0.00162	CcSEcCtD
Lubiprostone—Abdominal discomfort—Methotrexate—systemic scleroderma	0.00101	0.00162	CcSEcCtD
Lubiprostone—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00161	CcSEcCtD
Lubiprostone—Asthenia—Leflunomide—systemic scleroderma	0.00101	0.00161	CcSEcCtD
Lubiprostone—Feeling abnormal—Lisinopril—systemic scleroderma	0.000998	0.00159	CcSEcCtD
Lubiprostone—Connective tissue disorder—Prednisone—systemic scleroderma	0.000995	0.00159	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00099	0.00158	CcSEcCtD
Lubiprostone—Dizziness—Azathioprine—systemic scleroderma	0.000987	0.00157	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000966	0.00154	CcSEcCtD
Lubiprostone—Asthenia—Mycophenolic acid—systemic scleroderma	0.000964	0.00154	CcSEcCtD
Lubiprostone—Diarrhoea—Leflunomide—systemic scleroderma	0.000964	0.00154	CcSEcCtD
Lubiprostone—Abdominal pain—Lisinopril—systemic scleroderma	0.000957	0.00153	CcSEcCtD
Lubiprostone—Vomiting—Azathioprine—systemic scleroderma	0.000949	0.00151	CcSEcCtD
Lubiprostone—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000946	0.00151	CcSEcCtD
Lubiprostone—Rash—Azathioprine—systemic scleroderma	0.000941	0.0015	CcSEcCtD
Lubiprostone—Dermatitis—Azathioprine—systemic scleroderma	0.00094	0.0015	CcSEcCtD
Lubiprostone—Headache—Azathioprine—systemic scleroderma	0.000935	0.00149	CcSEcCtD
Lubiprostone—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000934	0.00149	CcSEcCtD
Lubiprostone—Dizziness—Leflunomide—systemic scleroderma	0.000932	0.00149	CcSEcCtD
Lubiprostone—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000922	0.00147	CcSEcCtD
Lubiprostone—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00092	0.00147	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000916	0.00146	CcSEcCtD
Lubiprostone—Pain—Mycophenolate mofetil—systemic scleroderma	0.000907	0.00145	CcSEcCtD
Lubiprostone—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000907	0.00145	CcSEcCtD
Lubiprostone—Vomiting—Leflunomide—systemic scleroderma	0.000896	0.00143	CcSEcCtD
Lubiprostone—Hypersensitivity—Lisinopril—systemic scleroderma	0.000892	0.00142	CcSEcCtD
Lubiprostone—Dizziness—Mycophenolic acid—systemic scleroderma	0.000889	0.00142	CcSEcCtD
Lubiprostone—Rash—Leflunomide—systemic scleroderma	0.000888	0.00142	CcSEcCtD
Lubiprostone—Dermatitis—Leflunomide—systemic scleroderma	0.000888	0.00142	CcSEcCtD
Lubiprostone—Mental disorder—Prednisone—systemic scleroderma	0.000887	0.00141	CcSEcCtD
Lubiprostone—Nausea—Azathioprine—systemic scleroderma	0.000886	0.00141	CcSEcCtD
Lubiprostone—Headache—Leflunomide—systemic scleroderma	0.000883	0.00141	CcSEcCtD
Lubiprostone—Malnutrition—Prednisone—systemic scleroderma	0.000881	0.00141	CcSEcCtD
Lubiprostone—Erythema—Prednisone—systemic scleroderma	0.000881	0.00141	CcSEcCtD
Lubiprostone—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000874	0.00139	CcSEcCtD
Lubiprostone—Asthenia—Lisinopril—systemic scleroderma	0.000869	0.00139	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000867	0.00138	CcSEcCtD
Lubiprostone—Vomiting—Mycophenolic acid—systemic scleroderma	0.000855	0.00136	CcSEcCtD
Lubiprostone—Rash—Mycophenolic acid—systemic scleroderma	0.000848	0.00135	CcSEcCtD
Lubiprostone—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000847	0.00135	CcSEcCtD
Lubiprostone—Headache—Mycophenolic acid—systemic scleroderma	0.000842	0.00134	CcSEcCtD
Lubiprostone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000839	0.00134	CcSEcCtD
Lubiprostone—Nausea—Leflunomide—systemic scleroderma	0.000837	0.00134	CcSEcCtD
Lubiprostone—Diarrhoea—Lisinopril—systemic scleroderma	0.000828	0.00132	CcSEcCtD
Lubiprostone—Ill-defined disorder—Prednisone—systemic scleroderma	0.000817	0.0013	CcSEcCtD
Lubiprostone—Dizziness—Lisinopril—systemic scleroderma	0.000801	0.00128	CcSEcCtD
Lubiprostone—Nausea—Mycophenolic acid—systemic scleroderma	0.000798	0.00127	CcSEcCtD
Lubiprostone—Malaise—Prednisone—systemic scleroderma	0.000795	0.00127	CcSEcCtD
Lubiprostone—Syncope—Prednisone—systemic scleroderma	0.00079	0.00126	CcSEcCtD
Lubiprostone—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000782	0.00125	CcSEcCtD
Lubiprostone—Loss of consciousness—Prednisone—systemic scleroderma	0.000774	0.00124	CcSEcCtD
Lubiprostone—Vomiting—Lisinopril—systemic scleroderma	0.00077	0.00123	CcSEcCtD
Lubiprostone—Rash—Lisinopril—systemic scleroderma	0.000763	0.00122	CcSEcCtD
Lubiprostone—Dermatitis—Lisinopril—systemic scleroderma	0.000763	0.00122	CcSEcCtD
Lubiprostone—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000762	0.00122	CcSEcCtD
Lubiprostone—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000761	0.00121	CcSEcCtD
Lubiprostone—Headache—Lisinopril—systemic scleroderma	0.000758	0.00121	CcSEcCtD
Lubiprostone—Myalgia—Prednisone—systemic scleroderma	0.00075	0.0012	CcSEcCtD
Lubiprostone—Anxiety—Prednisone—systemic scleroderma	0.000748	0.00119	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000745	0.00119	CcSEcCtD
Lubiprostone—Discomfort—Prednisone—systemic scleroderma	0.000741	0.00118	CcSEcCtD
Lubiprostone—Mental disorder—Methotrexate—systemic scleroderma	0.000741	0.00118	CcSEcCtD
Lubiprostone—Malnutrition—Methotrexate—systemic scleroderma	0.000736	0.00117	CcSEcCtD
Lubiprostone—Erythema—Methotrexate—systemic scleroderma	0.000736	0.00117	CcSEcCtD
Lubiprostone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000726	0.00116	CcSEcCtD
Lubiprostone—Dysgeusia—Methotrexate—systemic scleroderma	0.000721	0.00115	CcSEcCtD
Lubiprostone—Nausea—Lisinopril—systemic scleroderma	0.000719	0.00115	CcSEcCtD
Lubiprostone—Oedema—Prednisone—systemic scleroderma	0.000719	0.00115	CcSEcCtD
Lubiprostone—Shock—Prednisone—systemic scleroderma	0.000707	0.00113	CcSEcCtD
Lubiprostone—Nervous system disorder—Prednisone—systemic scleroderma	0.000705	0.00113	CcSEcCtD
Lubiprostone—Tachycardia—Prednisone—systemic scleroderma	0.000702	0.00112	CcSEcCtD
Lubiprostone—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000701	0.00112	CcSEcCtD
Lubiprostone—Skin disorder—Prednisone—systemic scleroderma	0.000698	0.00111	CcSEcCtD
Lubiprostone—Hyperhidrosis—Prednisone—systemic scleroderma	0.000695	0.00111	CcSEcCtD
Lubiprostone—Anorexia—Prednisone—systemic scleroderma	0.000685	0.00109	CcSEcCtD
Lubiprostone—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000683	0.00109	CcSEcCtD
Lubiprostone—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000674	0.00108	CcSEcCtD
Lubiprostone—Rash—Mycophenolate mofetil—systemic scleroderma	0.000669	0.00107	CcSEcCtD
Lubiprostone—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000668	0.00107	CcSEcCtD
Lubiprostone—Headache—Mycophenolate mofetil—systemic scleroderma	0.000665	0.00106	CcSEcCtD
Lubiprostone—Malaise—Methotrexate—systemic scleroderma	0.000664	0.00106	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000655	0.00105	CcSEcCtD
Lubiprostone—Cough—Methotrexate—systemic scleroderma	0.000643	0.00103	CcSEcCtD
Lubiprostone—Dyspepsia—Prednisone—systemic scleroderma	0.000633	0.00101	CcSEcCtD
Lubiprostone—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00063	0.00101	CcSEcCtD
Lubiprostone—Chest pain—Methotrexate—systemic scleroderma	0.000627	0.001	CcSEcCtD
Lubiprostone—Myalgia—Methotrexate—systemic scleroderma	0.000627	0.001	CcSEcCtD
Lubiprostone—Decreased appetite—Prednisone—systemic scleroderma	0.000625	0.000997	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000623	0.000993	CcSEcCtD
Lubiprostone—Fatigue—Prednisone—systemic scleroderma	0.00062	0.000989	CcSEcCtD
Lubiprostone—Discomfort—Methotrexate—systemic scleroderma	0.000619	0.000988	CcSEcCtD
Lubiprostone—Constipation—Prednisone—systemic scleroderma	0.000615	0.000981	CcSEcCtD
Lubiprostone—Feeling abnormal—Prednisone—systemic scleroderma	0.000593	0.000945	CcSEcCtD
Lubiprostone—Nervous system disorder—Methotrexate—systemic scleroderma	0.000589	0.00094	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000588	0.000938	CcSEcCtD
Lubiprostone—Skin disorder—Methotrexate—systemic scleroderma	0.000584	0.000931	CcSEcCtD
Lubiprostone—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000581	0.000927	CcSEcCtD
Lubiprostone—Anorexia—Methotrexate—systemic scleroderma	0.000573	0.000914	CcSEcCtD
Lubiprostone—Abdominal pain—Prednisone—systemic scleroderma	0.000568	0.000907	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000548	0.000874	CcSEcCtD
Lubiprostone—Dyspnoea—Methotrexate—systemic scleroderma	0.000536	0.000855	CcSEcCtD
Lubiprostone—Hypersensitivity—Prednisone—systemic scleroderma	0.00053	0.000845	CcSEcCtD
Lubiprostone—Dyspepsia—Methotrexate—systemic scleroderma	0.000529	0.000844	CcSEcCtD
Lubiprostone—Decreased appetite—Methotrexate—systemic scleroderma	0.000522	0.000834	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000519	0.000828	CcSEcCtD
Lubiprostone—Fatigue—Methotrexate—systemic scleroderma	0.000518	0.000827	CcSEcCtD
Lubiprostone—Asthenia—Prednisone—systemic scleroderma	0.000516	0.000823	CcSEcCtD
Lubiprostone—Pain—Methotrexate—systemic scleroderma	0.000514	0.00082	CcSEcCtD
Lubiprostone—Feeling abnormal—Methotrexate—systemic scleroderma	0.000495	0.00079	CcSEcCtD
Lubiprostone—Diarrhoea—Prednisone—systemic scleroderma	0.000492	0.000785	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000491	0.000784	CcSEcCtD
Lubiprostone—Dizziness—Prednisone—systemic scleroderma	0.000476	0.000759	CcSEcCtD
Lubiprostone—Abdominal pain—Methotrexate—systemic scleroderma	0.000475	0.000758	CcSEcCtD
Lubiprostone—Vomiting—Prednisone—systemic scleroderma	0.000457	0.000729	CcSEcCtD
Lubiprostone—Rash—Prednisone—systemic scleroderma	0.000453	0.000723	CcSEcCtD
Lubiprostone—Dermatitis—Prednisone—systemic scleroderma	0.000453	0.000723	CcSEcCtD
Lubiprostone—Headache—Prednisone—systemic scleroderma	0.00045	0.000719	CcSEcCtD
Lubiprostone—Hypersensitivity—Methotrexate—systemic scleroderma	0.000443	0.000706	CcSEcCtD
Lubiprostone—Asthenia—Methotrexate—systemic scleroderma	0.000431	0.000688	CcSEcCtD
Lubiprostone—Nausea—Prednisone—systemic scleroderma	0.000427	0.000681	CcSEcCtD
Lubiprostone—Diarrhoea—Methotrexate—systemic scleroderma	0.000411	0.000656	CcSEcCtD
Lubiprostone—Dizziness—Methotrexate—systemic scleroderma	0.000397	0.000634	CcSEcCtD
Lubiprostone—Vomiting—Methotrexate—systemic scleroderma	0.000382	0.00061	CcSEcCtD
Lubiprostone—Rash—Methotrexate—systemic scleroderma	0.000379	0.000605	CcSEcCtD
Lubiprostone—Dermatitis—Methotrexate—systemic scleroderma	0.000379	0.000604	CcSEcCtD
Lubiprostone—Headache—Methotrexate—systemic scleroderma	0.000376	0.000601	CcSEcCtD
Lubiprostone—Nausea—Methotrexate—systemic scleroderma	0.000357	0.00057	CcSEcCtD
